UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission file number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaw ...

EXHIBIT 99.1 Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT PITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug develop ...

Predictive Oncology Inc. (NASDAQ:POAI) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q3 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. And I would now like to hand the conference over to your speaker for today, Mr. Glen ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) | Delaware | 33-1007393 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 91 43r ...

Predictive Oncology, Inc. (NASDAQ:POAI) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-o ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) | Delaware | 33 ...

Financial Data and Key Metrics Changes - As of March 31, 2023, cash and cash equivalents decreased to $18.6 million from $22.1 million as of December 31, 2022 [29] - Shareholders' equity stood at $18.6 million compared to $21.8 million as of December 31, 2022 [77] - First quarter 2023 revenue was $0.2 million, down from $0.3 million in the first quarter of 2022, with a gross margin of 50% compared to 65% in the previous year [77] Business Line Data and Key Metrics Changes - The PeDAL platform is highlighted as a significant asset, with the ability to predict tumor responses with 92% accuracy, aiding in drug discovery [8] - The company has launched 11 cancer therapies currently on the market and is sponsoring an additional 160 compounds [9] Market Data and Key Metrics Changes - The company is positioned to participate in the $1 billion artificial intelligence drug discovery market, projected to grow annually at a compound rate of more than 30% [51] Company Strategy and Development Direction - The company aims to leverage its PeDAL platform and partnerships to mitigate clinical risks and enhance drug discovery processes [82] - Recent partnerships with Cancer Research Horizon (CRH) and Cvergenx are expected to expand the company's reach in oncologic drug development [85][87] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about revenue potential in the next six months, indicating that it will be greater than the previous year [46] - The company is working towards breakeven, with expectations of achieving this within the next 12 months [103] Other Important Information - The company has no debt, indicating a strong balance sheet [29] - A recent lawsuit was mentioned, with management asserting a strong commitment to resolving it with minimal impact on investors [14] Q&A Session Summary Question: What is the timeline for breakeven and how many molecules have been looked at under the partnership with Cancer Research? - Management confirmed that they are working on one compound, and successful development will trigger financial milestones [35] Question: Can you clarify the situation regarding David Smith stepping down from the Board? - Management explained that David Smith stepped down due to a conflict with his law firm but will remain as a Board adviser and lead corporate counsel [99] Question: What are the expectations for revenue growth in the next quarter? - Management expressed hope for revenue growth within the fiscal year, noting that no machines were sold in the last quarter but a new agreement in Canada was signed [103]

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Del ...

Financial Data and Key Metrics Changes - The company is transitioning from R&D and product development to the validation, commercialization, and launch of its PEDAL drug discovery platform [15][28] - The sales cycle for the PEDAL platform is approximately 12 months, which impacts revenue recognition [46][48] Business Line Data and Key Metrics Changes - The company has partnered with Cancer Research Horizons to integrate its PEDAL platform into drug discovery processes, enhancing visibility and credibility in the market [15][16] - A collaboration with Cvergenx, Inc. aims to develop a genomics-based approach to precision radiation therapy using the PEDAL platform [18][20] Market Data and Key Metrics Changes - The company is focusing on oncology drug discovery and development, leveraging its unique AI capabilities and biorepository of tumor samples [8][9] - The market for AI in biopharma is growing, with increasing adoption of AI technologies for drug discovery [50] Company Strategy and Development Direction - The company is rebranding and repositioning itself to emphasize its unique AI-driven approach to drug discovery [5][8] - There is a strategic focus on expanding the intellectual property portfolio and enhancing partnerships with academic and research institutions through the Accelerating Compound Exploration program [10][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges of being an innovator in the biopharma space, emphasizing the need to demonstrate how their platform fits into existing workflows [45][48] - The FDA's acceptance of AI technologies is seen as a positive development for the company's future prospects [72] Other Important Information - The company has engaged a leading investor relations firm to raise awareness among Wall Street constituents [27] - A new Scientific Advisory Board is being formed to focus on emerging market opportunities in AI and oncology [25][26] Q&A Session Summary Question: Did the departure of Dr. Julia Kirshner hurt the company? - Management stated that her departure did not hinder technological progress, as the necessary expertise remains within the company [34][40] Question: What is the expected timeline for achieving breakeven status? - The CFO indicated that predicting a timeline for breakeven is challenging due to the variability in sales cycles and contract milestones [62] Question: What is the timeframe from signing a contract to receiving the first payment? - The company expects initial payments within 10 to 12 weeks after contract signing, depending on project size [68][70] Question: Will key executives purchase stock to show confidence in the company? - Management expressed interest in purchasing stock but is currently in a blackout period preventing such actions [89][91] Question: What is the target share price post-reverse split? - The management indicated that the ideal post-split share price would be in the range of $3.50 to $4.50, but this will depend on market conditions at the time [96][100] Question: How does the reverse split benefit shareholders? - Management clarified that while the reverse split does not change the actual value, a higher share price could attract more investors [110][111]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-36790 PREDICTIVE ONCOLOGY INC. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or other jurisdiction (IRS Employe ...